Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
125.89
+0.45 (+0.36%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
69
70
Next >
Moderna Rallies On Merck Collaboration: Can Drugmaker Replace COVID Vaccine Revenue?
October 12, 2022
In late 2020, when the world was searching for a vaccine or cure for COVID-19, the price action in Moderna Inc (NASDAQ: MRNA) was discussed frequently on Benzinga's PreMarket Prep show.
Via
Benzinga
Why Moderna Stock Is Bolting Higher Today
October 12, 2022
A cancer vaccine deal with pharma heavyweight Merck is lighting a fire underneath the biotech's shares today.
Via
The Motley Fool
Why Is Moderna (MRNA) Stock Up 10% Today?
October 12, 2022
The medical community is witnessing a potential watershed moment in vaccine development. And MRNA stock traders are in a buying mood.
Via
InvestorPlace
Yet Another Good News For Moderna, FDA Approves Its New Omicron Adapted COVID-19 Shot
October 12, 2022
Via
Benzinga
Moderna Shares Are Surging After Merck Exercised Personalized Cancer Vaccine Pact
October 12, 2022
Via
Benzinga
Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment
October 12, 2022
The companies are targeting high-risk melanoma patients.
Via
Investor's Business Daily
With Meaningful Upside, This Cancer Stock Earns Analyst Upgrade
October 11, 2022
Via
Benzinga
Merck (MRK) Stock Jumps 4% on Positive Trial Data
October 10, 2022
Merck took a big gamble in buying a therapeutic as part of an acquisition deal and it appears to have paid off, sending MRK stock soaring.
Via
InvestorPlace
Centre Piece Of Merck's $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular Trial
October 10, 2022
Via
Benzinga
Why Moderna Stock Is Moving Higher Today
October 12, 2022
Moderna Inc (NASDAQ: MRNA) shares are trading higher Wednesday after the company announced Merck & Company Inc (NYSE: MRK) has exercised its option to jointly develop and commercialize a personalize
Via
Benzinga
3 Dividend Stocks in Warren Buffett's Secret Portfolio Most Likely to Soar in Q4
October 12, 2022
These stocks could add to Buffett's fortune by the end of 2022.
Via
The Motley Fool
London Bridge: BoE Again Intervenes in Bond Market, Raising Stability Concerns
October 11, 2022
(Tuesday Market Open) After separate warnings Monday of possible recession and “fragile liquidity” from two influential global financial leaders, investors woke Tuesday to fresh troubling news from the...
Via
Benzinga
Merck Collaborates Ginkgo Bioworks to Improve Active Pharmaceutical Ingredient Manufacturing
October 11, 2022
Via
Benzinga
PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers
October 11, 2022
Via
Benzinga
Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout
October 10, 2022
The company said it led to a "profound" improvement for patients with PAH.
Via
Investor's Business Daily
UK Study Shows Merck's COVID-19 Antiviral Pill Did Not Cut Hospitalization Risk
October 07, 2022
Via
Benzinga
What Is Going on With Ginkgo Bioworks (DNA) Stock Today?
October 11, 2022
Ginkgo's planned collab with a pharma giant should spark a rally in DNA stock - but then, sometimes logic doesn't prevail on Wall Street.
Via
InvestorPlace
Merck To Rally Over 29%? Here Are 5 Other Price Target Changes For Tuesday
October 11, 2022
Atlantic Equities raised Merck & Co., Inc. (NYSE: MRK) price target from $110 to $116. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock. Merck shares fell 0.8% to...
Via
Benzinga
Failure Of This Merck Study Is A 'Material Risk' But Analysts Are 'Extremely Bullish'
October 10, 2022
Merck & Co. Inc. (NYSE: MRK) seems well positioned to surpass 2023 consensus estimates, driven by margin potential, according to Guggenheim. The Analyst: Seamus Fernandez upgraded the rating for Merck...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
October 10, 2022
Upgrades
Via
Benzinga
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
October 10, 2022
People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.
Via
Benzinga
10 Dividend Growth Stocks For October 2022
October 09, 2022
After two months off, I'm back with another edition of my monthly series, 10 Dividend Growth Stocks. I rank a selection of Dividend Radar stocks in this series and present the ten top-ranked stocks for...
Via
Talk Markets
3 Great Dividend Stocks to Buy in October
October 08, 2022
Their dividends should be much bigger in the future.
Via
The Motley Fool
Stocks Snap Weekly Losing Streaks Despite Selloff
October 07, 2022
Traders are concerned a strong jobs market may encourage the Federal Reserve to double down on its hawkish policy, with bond yields rising in response.
Via
Talk Markets
Amazon Halts Delivery Bots; Merck's Covid-19 Pill Didn't Reduce Risk; Samsung Profits Slip; Adidas Reviews Relationship With Kanye: Top Stories Friday, Oct. 7
October 07, 2022
Benzinga
Via
Benzinga
Why Guardant Health Topped the Market on Thursday
October 06, 2022
Add another name to the list of the cancer-diagnostic company's bulls.
Via
The Motley Fool
Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" Competition
October 06, 2022
Via
Benzinga
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
October 06, 2022
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera
Via
Benzinga
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial
October 05, 2022
Via
Benzinga
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
October 03, 2022
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.
Via
Talk Markets
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
69
70
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.